More Effectively Using Registries to suppOrt PAtient-centered Regulatory and HTA decision-making

Resultado final

Report on evidence needs defined by stakeholders across the lifecycle of medicinal products. Report contains summary of evidence needs formulated such that they can be translated to quantifiable concepts for use in desig and analyses of trials and RWD from registries.

Registries identification machine learning tool

Natural language processing-powered tool for identifications of the registries and key opinion leaders based on automated systematic literature review (including, code, documentation, and methodology description)

Data collection (feasibility)

report on the description of data from multiple sclerosis patients treated with rituximab and dimethyl fumarate from all contributing registries. This will, in addition to treatment information, include personal, clinical and other treatment data and be specified per country.

Dissemination and exploitation plan

A report of the communication and dissemination plan will be written on the dissemination strategy towards key stakeholders to ensure an uptake of the project outcomes. The plan will include the set-up of More-EUROPA's website with content relevant for both the project members and the wider, lay-men’s audience, and will cover social media activities presentation templates and networking activities.

Registries identification guidelines

Recommendations for registries identification; modelling plan for the tool development

Stakeholder kick-off

A report will be written on the kick-off stakeholder conference with a project overview and appraisal of key stakeholders’ perspectives on implementing registry-based RWD/RWE in regulatory and HTA decision making.

Report on the state of the art and unmet needs

Detailed document discussing the current practices of registry identification and assessment in Europe and worldwide.

Publicaciones

Real-World Data Included in Post-authorisation Measures: A Case Study of Approved Advanced Therapy Medicinal Products in the European Union between 2013 and 2024

Autores: Diogo Almeida; Diana Mandslay; Peter G. M. Mol; Bruno Sepodes; Carla Torre
Publicado en: BioDrugs, 2025, ISSN 1179-190X
Editor: Springer Nature Link
DOI: 10.1007/S40259-025-00737-X

Timing of Cardiac Resynchronization Therapy Following Stable Medical Therapy in Patients With Heart Failure

Autores: Alessandro Villaschi, Christian Basile, Lina Benson, Paolo Gatti, William T. Abraham, Michael Böhm, Biykem Bozkurt, Javed Butler, Gianluigi Condorelli, Cecilia Linde, Marco Metra, Wilfried Mullens, Peter Mol, Shelley Zieroth, Raffaele Scorza, Lars H. Lund, Fredrik Gadler, Gianluigi Savarese
Publicado en: JACC: Heart Failure, Edición 13, 2025, ISSN 2213-1779
Editor: Elsevier BV
DOI: 10.1016/J.JCHF.2025.102515

Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes. Data from the Swedish Heart Failure and Swedish National Diabetes Registries

Autores: Markus Wallner, Mattia Emanuele Biber, Davide Stolfo, Gianfranco Sinagra, Lina Benson, Ulf Dahlström, Soffia Gudbjörnsdottir, Francesco Cosentino, Peter G M Mol, Giuseppe M C Rosano, aved Butler, Marco Metra, MD, Lars H Lund, Giulia Ferrannini, Gianluigi
Publicado en: European Heart Journal - Cardiovascular Pharmacotherapy, ISSN 2055-6845
Editor: Oxford
DOI: 10.1093/EHJCVP/PVAE026

Associations between cardiac resynchronization therapy and clinical outcomes according to the atrial fibrillation status in patients with heart failure with reduced ejection fraction

Autores: Renzo Laborante, Valeria Valente, Lina Benson, Paolo Gatti, Christian Basile, Alessandro Villaschi, Peter Moritz Becher, Domenico D’Amario, Carin Corovic-Cabrera, Fredrik Gadler, Gianluigi Savarese, Raffaele Scorza
Publicado en: Europace, Edición 27, 2025, ISSN 1099-5129
Editor: Oxford University Press (OUP)
DOI: 10.1093/EUROPACE/EUAF296

Stakeholders’ Perspectives Toward the Use of Patient Registry Data for Decision-Making on Medicines: A Cross-Sectional Survey

Autores: Fabian Windfuhr; Sieta T. de Vries; Maria Melinder; Tanja Dahlqvist; Diogo Almeida; Bruno Sepodes; Carla Torre; Björn Wettermark; Peter G. M. Mol
Publicado en: Drug Safety, 2025, ISSN 1179-1942
Editor: Springer Nature Link
DOI: 10.1007/S40264-025-01528-7

Safety of continuing mineralocorticoid receptor antagonist treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: Data from Swedish Heart Failure Registry

Autores: Federica Guidetti, Lars H. Lund, Lina Benson, Camilla Hage, Francesca Musella, Davide Stolfo, Peter G.M. Mol, Andreas J. Flammer, Frank Ruschitzka, Ulf Dahlstrom, Giuseppe M.C. Rosano, Oscar Ö. Braun, Gianluigi Savarese
Publicado en: European Journal of Heart Failure, 2023, ISSN 1879-0844
Editor: Wiley
DOI: 10.1002/ejhf.3049

BMC Medicine

Autores: Olmo R. van den Akker; Susanne Stark; Daniel Strech
Publicado en: BMC Medicine, 2024, ISSN 1741-7015
Editor: BioMed Central
DOI: 10.1186/S12916-024-03799-W

Eligibility for vericiguat in a real-world heart failure population according to trial, guideline and label criteria: Data from the Swedish Heart Failure Registry

Autores: Nguyen NV, Lindberg F, Benson L, Ferrannini G, Imbalzano E, Mol PGM, Dahlström U, Rosano GMC, Ezekowitz J, Butler J, Lund LH, Savarese G.
Publicado en: European Journal of Heart Failure, ISSN 1879-0844
Editor: Wiley
DOI: 10.1002/EJHF.2939

Lung Cancer

Autores: Geeske F Grit; Esmée van Geffen; Ruben Malmberg; Roelof van Leeuwen; Stefan Böhringer; Hans JM Smit; Pepijn Brocken; Job FH Eijsink; Esther Dronkers; Pim Gal; Eva Jaarsma; Regine JHM van Drie-Pierik; Anne MP Eldering-Heldens; AN Machteld Wymenga; Peter GM Mol; Juliëtte Zwaveling; Doranne Hilarius
Publicado en: Lung Cancer, 2024, ISSN 0169-5002
Editor: Elsevier BV
DOI: 10.1016/J.LUNGCAN.2024.107950

RWD16 An AI-Powered Tool to Identify and Assess Fit-for-Use Registries for Drug Development and Evaluation

Autores: Ghinwa Y. Hayek, Boris Kopin, Sonia Zebachi, Gaëtan Pinon, Basile Ferry, Elisabeth Bakker, Alexandre Macquin, Sieta de Vries, Peter GM. Mol, Billy Amzal
Publicado en: Value in Health, Edición 28, 2025, ISSN 1098-3015
Editor: Elsevier BV
DOI: 10.1016/J.JVAL.2025.09.2766

On the Concepts, Methods, and Use of “Probability of Success” for Drug Development Decision‐Making: A Scoping Review

Autores: Cetinyurek-Yavuz, A.; Fayyad, M.B.N.; Jiang, Ce; Brion Bouvier, F.; Beji, C.; Zebachi, S.; Hayek, G.Y.; Amzal, B.; Porcher, R.; Tanniou, J.; Roes, K.C.B.; Rodwell, L.; Rodwell, L.
Publicado en: Clinical Pharmacology &Therapeutics, 2025, ISSN 1532-6535
Editor: Wiley
DOI: 10.1002/CPT.3571

Characteristics, use of guideline–recommended medical therapies and clinical outcomes of patients with heart failure not enrolled in a quality registry: a comparison with the Swedish Heart Failure Registry

Autores: Ailema González-Ortiz, Paul Hjemdahl, Faizan Mazhar, Alessandro Bosi, Anne-Laure Faucon, Gianluigi Savarese, Lars H Lund, Juan Jesus Carrero
Publicado en: European Heart Journal - Quality of Care and Clinical Outcomes, Edición 11, 2025, ISSN 2058-5225
Editor: Oxford University Press (OUP)
DOI: 10.1093/EHJQCCO/QCAF019

Eligibility for omecamtiv mecarbil in a real-world heart failure population: Data from the Swedish Heart Failure Registry

Autores: Lindberg F, Øigaard N, Metra M, Rosano GMC, Dahlström U, Mol P, Hage C, Lund LH, Savarese G.
Publicado en: PLoS ONE, ISSN 1932-6203
Editor: PLOS
DOI: 10.1371/JOURNAL.PONE.0303348

European Journal of Heart Failure

Autores: Benedikt N. Beer; Lina Benson; Christian Basile; Benedikt Schrage; Peter Moritz Becher; Stefan Blankenberg; Paulus Kirchhof; Barna Szabó‐Söderberg; Marco Metra; Anne Lindberg; Egidio Imbalzano; Giuseppe M. C. Rosano; Patric Karlström; Peter G.M. Mol; Raffaele Scorza; Lars H. Lund; Felix Lindberg; Gianluigi Savarese
Publicado en: European Journal of Heart Failure, 2025, ISSN 1388-9842
Editor: Elsevier BV
DOI: 10.1002/EJHF.70046

Leveraging patient experience data to guide medicines development, regulation, access decisions and clinical care in the EU

Autores: Almeida D, Umuhire D, Gonzalez-Quevedo R, António A, Burgos JG, Verpillat P, Bere N, Sepodes B, Torre C.
Publicado en: Frontiers in Medicine, ISSN 2296-858X
Editor: Frontiers
DOI: 10.3389/FMED.2024.1408636

Sex differences in the prognostic role of achieving target doses of heart failure medications: Data from the Swedish Heart Failure Registry

Autores: Amerigo Ferrari, Davide Stolfo, Alicia Uijl, Nicola Orsini, Lina Benson, Gianfranco Sinagra, Peter Mol, Sieta T. de Vries, Ulf Dahlström, Giuseppe Rosano, Lars H. Lund, Gianluigi Savarese
Publicado en: European Journal of Heart Failure, ISSN 1879-0844
Editor: Wiley
DOI: 10.1002/EJHF.3272

Navigating the Real World: A Scoping Review of Structured Frameworks to Effectively Identify, Evaluate, and Select Real‐World Data Sources for Fit‐for‐Purpose Studies

Autores: Sonia Zebachi, Julien Tanniou, Elisabeth Bakker, Sieta T. de Vries, Rossella Di Bidino, Entela Xoxi, Anna Glaser, Gianluigi Savarese, Jan Hillert, Peter G. M. Mol, Kelly Plueschke, Billy Amzal, Ghinwa Y. Hayek, Jeverson Moreira
Publicado en: Clinical Pharmacology & Therapeutics, Edición 118, 2025, ISSN 0009-9236
Editor: Wiley
DOI: 10.1002/CPT.3746

Withdrawal of Guideline-Directed Medical Therapy in Patients With Heart Failure and Improved Ejection Fraction

Autores: Christian Basile, Felix Lindberg, Lina Benson, Federica Guidetti, Ulf Dahlström, Massimo Francesco Piepoli, Peter Mol, Raffaele Scorza, Aldo Pietro Maggioni, Lars H. Lund, Gianluigi Savarese
Publicado en: Circulation, Edición 151, 2025, ISSN 0009-7322
Editor: Ovid Technologies (Wolters Kluwer Health)
DOI: 10.1161/CIRCULATIONAHA.124.072855

Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry

Autores: Becher PM, Savarese G, Benson L, Dahlström U, Karlström P, Mol PGM, Metra M, Bhatt DL, Pitt B, Lund LH.
Publicado en: European Heart Journal - Cardiovascular Pharmacotherapy, ISSN 2055-6845
Editor: Oxford
DOI: 10.1093/EHJCVP/PVAD012

Decision‐Making Criteria and Methods for Initiating Late‐Stage Clinical Trials in Drug Development From a Multi‐Stakeholder Perspective: A Scoping Review

Autores: Ce Jiang, Céline Beji, Sonia Zebachi, Ghinwa Y. Hayek, Aysun Cetinyurek‐Yavuz, Muhammad Bergas N. Fayyad, Laura Rodwell, Kit C. B. Roes, Billy Amzal, Christoph Gerlinger, Raphaël Porcher, Julien Tanniou
Publicado en: Clinical Pharmacology & Therapeutics, Edición 117, 2025, ISSN 0009-9236
Editor: Wiley
DOI: 10.1002/CPT.3566

Ethics practices associated with reusing health data: An assessment of patient registries

Autores: Olmo van den Akker, Susanne Stark, Daniel Strech
Publicado en: medRxiv, ISSN 0000-0000
Editor: x
DOI: 10.1101/2024.04.26.24306459

What Are Unmet Needs for the Use of Registries in Regulatory/HTA Decision-Making in Europe? A Survey-Based Approach From the More-EUROPA Project

Autores: J. Moreira, J. Tanniou, P. Tang, P. Godbillot, F.Ahrens, B. Amzal
Publicado en: Value in Health, ISSN 1098-3015
Editor: Blackwell Publishing Inc.
DOI: 10.1016/J.JVAL.2023.09.2150

Criteria and Methods Applied to Decision-Making to Embark on Late-Stage Clinical Trials With a Multi-Stakeholder Perspective

Autores: C. Jiang, J.Tanniou, B. Amzal
Publicado en: Value in Health, ISSN 1098-3015
Editor: Blackwell Publishing Inc.
DOI: 10.1016/J.JVAL.2023.09.2148

Decision-Making Criteria and Methods for Initiating Late-Stage Clinical Trials from a Multi-Stakeholder Perspective: A Scoping Review

Autores: Ce Jiang, Céline Beji, Sonia Zebachi, Ghinwa Hayek, Aysun CetinyurekYavuz, Bergas Fayyad, Laura Rodwell, Kit C.B. Roes, Billy Amzal, Christoph Gerlinger, Raphaël Porcher, Julien Tanniou
Publicado en: 2025
Editor: PSI 2025 Conference

Decision-Making Criteria and Methods for Initiating Late-Stage Clinical Trials in Drug Development From a Multi-Stakeholder Perspective: A Scoping Review

Autores: Ce Jiang, Céline Beji, Sonia Zebachi, Ghinwa Hayek, Aysun CetinyurekYavuz, Bergas Fayyad, Laura Rodwell, Kit C.B. Roes, Billy Amzal, Christoph Gerlinger, Raphaël Porcher, Julien Tanniou
Publicado en: 2025
Editor: SnB Conference

An AI powered tool to identify and assess fit-for-use registries for real-world evidence

Autores: Ghinwa Y. Hayek, Pascal Godbillot, Coriande Clemente, Sonia Zebachi, Gaëtan Pinon, Boris Kopin, Elisabeth Bakker, Sieta T. de Vries, Peter G.M. Mol, Billy Amzal
Publicado en: European Drug Utilization Conference 2025, 2025
Editor: European Drug Utilization Conference

Existing Automated Tools to Assist Evidence Generation and Better Qualification of Registries and Real-World Data: A Systematic Review From the More-EUROPA Project

Autores: P. Godbillot, P. Tang, J. Moreira, J. Tanniou, S. Zebachi, B. Amzal
Publicado en: Value in Health, ISSN 1098-3015
Editor: Elsevier
DOI: 10.1016/J.JVAL.2023.09.2120

Navigating the Real World: A Scoping Review of Structured Frameworks to Effectively Identify, Evaluate, and Select Real-World Data Sources for Fit-for-Purpose Studies

Autores: Sonia Zebachi, Julien Tanniou, Elisabeth Bakker, Sieta T. de Vries, Rossella di Bidino, Entela Xoxi, Anna Glaser, Gianluigi Savarese, Jan Hillert, Peter G.M. Mol, Kelly Plueschke, Ghinwa Hayek, Billy Amzal, Jeverson Moreira
Publicado en: European Drug Utilization Conference 2025, 2025
Editor: European Drug Utilization Conference 2025

Existing Automated Tools to Assist Evidence Generation and Better Qualification of Registries and Real-World Data: A Systematic Review From the More-EUROPA Project

Autores: S. Zebachi, J. Moreira, J. Tanniou, P. Godbillot, P. Tang, B. Amzal
Publicado en: Value in Health, ISSN 1098-3015
Editor: Blackwell Publishing Inc.
DOI: 10.1016/J.JVAL.2023.09.2089

Resultado final

Publicaciones

Compartir esta página Compartir esta página en las redes sociales

Descargar el PDF Descargar el contenido de la página